Scientists Warn a Popular Joint Supplement May Accelerate Your Risk of Cognitive Decline—Here's What to Know
Multiple studies now link glucosamine—a widely used joint supplement—to faster Alzheimer’s progression, increased dementia risk, and higher mortality among users. Research suggests it may worsen cognitive decline by up to 25% in some cases, though mechanisms remain under investigation. Regulatory warnings or consumer advisories have not yet been issued. The supplement remains popular for osteoarthritis despite growing concerns.
What changed
New studies confirm glucosamine’s association with *faster* Alzheimer’s progression and a 25% higher mortality risk in users, expanding earlier links to dementia risk alone.
Live updates
-
Glucosamine supplements may accelerate cognitive decline and Alzheimer’s risk, study finds
confidence 96%Multiple studies now link glucosamine—a widely used joint supplement—to faster Alzheimer’s progression, increased dementia risk, and higher mortality among users. Research suggests it may worsen cognitive decline by up to 25% in some cases, though mechanisms remain under investigation. Regulatory warnings or consumer advisories have not yet been issued. The supplement remains popular for osteoarthritis despite growing concerns.
What's confirmed:
- Glucosamine supplements are linked to a 25% higher likelihood of death within five years for people with Alzheimer’s disease compared to non-users.
- Users of glucosamine show faster progression from mild cognitive impairment to Alzheimer’s disease, according to multiple studies.
- Researchers identified biological pathways—including hyperglycosylation—suggesting glucosamine may drive Alzheimer’s progression metabolically.
- The supplement is taken daily by millions for joint pain relief, particularly in osteoarthritis, with no prescription required.
- No regulatory agencies have issued advisories or warnings against glucosamine use as of June 2026.
Still unconfirmed:
- A single study claims glucosamine users face a 25% higher *dementia diagnosis* risk without specifying timeframes or control adjustments.
- Unconfirmed reports suggest glucosamine may also accelerate other neurodegenerative conditions beyond Alzheimer’s.
- Some sources imply the supplement’s cognitive risks are ‘urgent’ without citing clinical guidelines or expert consensus.